Skip to main content
. 2021 Mar;13(3):1485–1494. doi: 10.21037/jtd-20-3075

Table 2. Leading symptoms in symptomatic patients categorized by stage.

Symptoms ALL, N=200** I, N=21 II, N=7 III, N=60 IV, N=112
Respiratory symptoms, n (%)
   Cough 40 (20.0) 0 (0.00) 2 (28.6) 19 (31.7) 19 (17.0)
   Dyspnea 20 (10.0) 0 (0.00) 0 (0.00) 7 (11.7) 13 (11.6)
   Hemoptysis 23 (11.5) 3 (14.3) 2 (28.6) 5 (8.33) 13 (11.6)
   Chest pain 20 (10.0) 1 (4.76) 1 (14.3) 8 (13.3) 10 (8.93)
   Exacerbation/respiratory infection 30 (15.0) 10 (47.6) 2 (28.6) 10 (16.7) 8 (7.14)
Non-respiratory symptoms, n (%)
   Musculoskeletal pain 23 (11.5) 4 (19.0) 0 (0.00) 2 (3.33) 17 (15.2)
   Dysphagia 3 (1.50) 0 (0.00) 0 (0.00) 1 (1.67) 2 (1.79)
   Neurological deficits 5 (2.50) 0 (0.00) 0 (0.00) 0 (0.00) 5 (4.46)
   Constitutional syndrome 25 (12.5) 3 (14.3) 0 (0.00) 4 (6.67) 18 (16.1)
   Other symptoms* 11 (5.50) 0 (0.00) 0 (0.00) 4 (6.67) 7 (6.25)

*, other symptoms: hoarseness, superior vena cava syndrome, abdominal pain and palpation of subcutaneous lesion; **, from symptomatic patients (n=201), one has missing information about stage.